🔎 Trials Near Me

Beranda › Leukemia Mieloid Akut › Vermont › Burlington

Uji klinis Leukemia Mieloid Akut di Burlington, VT

7 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Burlington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Menerima pesertaFase 2
  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05554393

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Menerima pesertaFase 3
  • University of Vermont and State Agricultural College, Burlington
6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Menerima pesertaFase 3
  • University of Vermont Medical Center, Burlington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Menerima pesertaFase 1
  • University of Vermont, Burlington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788

Uji klinis Leukemia Mieloid Akut di kota lain

Studi lain di Burlington

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.